Chronic myeloid leukaemia (CML) · Data

technologies

7

Allogeneic stem cell transplantation Cytogenetics and FISH Cytokines & engineered cytokines Cytotoxic chemotherapy MRD / molecular residual disease testing Residual disease kinetics (BCR-ABL halving and ctDNA slopes)Small-molecule kinase inhibitors

targets

18

ABCB1 ABL1 BCR::ABL1 (Philadelphia chromosome)BLK DDR2 receptor kinase Elongation factor 2 (EEF2)FGR FYN GAB2 GRB2 HCK kinase IFNAR2 Interferon alpha receptor (IFNAR1)KIT LYN kinase SRC family kinases SRMS YES1

drugs

16

ApprovedSmall-molecule allosteric ABL1 inhibitor (STAMP)

Asciminib · Scemblix

ApprovedSmall-molecule BCR-ABL1/SRC TKI

Bosutinib · Bosulif

ApprovedAlkylating agent (alkyl sulfonate)

Busulfan · Myleran / Busulfex

ApprovedPyrimidine nucleoside analogue (antimetabolite)

Cytarabine · Cytosar-U (historic)

ApprovedSmall-molecule kinase inhibitor (BCR::ABL1, SRC)

Dasatinib · Sprycel

ApprovedOral second-generation BCR-ABL tyrosine kinase inhibitor

Flumatinib

ApprovedOral ribonucleotide reductase inhibitor (cytoreductive)

Hydroxyurea (hydroxycarbamide) · Hydrea / Droxia / Siklos

ApprovedSmall-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA)

Imatinib · Gleevec

HistoricRecombinant type I interferon (cytokine)

Interferon alfa-2a/2b · Roferon-A / Intron A / Sylatron

HistoricOral alkylating sugar alcohol

Mitobronitol · Myelobromol

ApprovedSmall-molecule BCR-ABL1 TKI (second generation)

Nilotinib · Tasigna

ApprovedOral third-generation BCR-ABL tyrosine kinase inhibitor

Olverembatinib

ApprovedProtein synthesis inhibitor (cephalotaxine ester)

Omacetaxine mepesuccinate · Synribo

HistoricOral alkylating-type cytotoxic

Pipobroman · Vercyte

ApprovedSmall-molecule kinase inhibitor (pan-BCR::ABL1 incl. T315I)

Ponatinib · Iclusig

Phase 3Oral kinase inhibitor

Radotinib

companies

13

Ascentage Pharma Bristol Myers Squibb Hansoh Pharmaceutical Il-Yang Pharmaceutical Merck & Co. (MSD)Natco Pharma Novartis Otsuka Pharmaceutical Pfizer (incl. Seagen)Roche / Genentech Shenzhen TargetRx Takeda Teva Pharmaceuticals

institutions

3

Fox Chase Cancer Center OHSU Knight Cancer Institute University of Chicago Medicine Comprehensive Cancer Center

pathways

5

BCR::ABL1 (Philadelphia chromosome)Chronic myeloid leukaemia (KEGG map)Drivers, passengers & the two-hit model PI3K / AKT / mTOR RAS / RAF / MEK / ERK (MAPK)

terms

8

Aneuploidy and chromosomal instability as the cause of cancer BCR::ABL1 kinase domain mutations (T315I and others)Clonal evolution and the ecological view of cancer Drug resistance (primary and acquired)Minimal / molecular residual disease (MRD)Oncogene addiction Sokal and ELTS risk scores (chronic myeloid leukaemia)Somatic mutation theory of cancer

trials

17

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia DASISION Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients Study of Olverembatinib (HQP1351) in Patients With CML-CP Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

collections

1

Leukemia & Lymphoma Society (LLS)

people

5

Adrian Ochsenbein Brian Druker Bud Romine Janet Rowley Timothy P. Hughes

key papers

2

First imatinib trial: a pill that switched off the enzyme driving chronic myeloid leukaemia IRIS: imatinib versus interferon plus cytarabine as first treatment for chronic myeloid leukaemia

journals

4

Clinical lymphoma, myeloma & leukemia Current hematologic malignancy reports Leukemia & lymphoma Leukemia research

biomarkers

2

BCR::ABL1 T315I BCR::ABL1 transcript (Philadelphia chromosome, quantitative PCR)

DataChronic myeloid leukaemia (CML)

Data

Related pages

Similar pages

technologies

targets

drugs

companies

institutions

pathways

terms

trials

collections

people

key papers

journals

biomarkers

Machine-readable versions

DataChronic myeloid leukaemia (CML)

Data

Related pages

Similar pages

technologies

targets

drugs

companies

institutions

pathways

terms

trials

collections

people

key papers

journals

biomarkers

Machine-readable versions